Ottimo Pharma Limited
10650475
Healthy
- Current liabilities exceed current assets (-10)
Details
Compliance
Last accounts
31/12/2025
group
Next accounts due
30/09/2027
Confirmation statement
Last: 21/01/2026
Due 04/02/2027
Industry
Officers
director · Since 13/11/2020
INVESTOR
ITALIAN · SWITZERLAND · Age 56
Also on 8 other boards
director · Since 18/12/2024
GENERAL PARTNER/MEMBER AT ORBIMED ADVISO
AMERICAN · UNITED STATES · Age 66
director · Since 17/03/2025
DIRECTOR
AMERICAN · UNITED STATES · Age 70
Also on 1 other board
Persons with Significant Control
Former PSCs
Dr William James Jonathan Finlay
Ceased 06/04/2017
Dr James Edward Coleman
Ceased 06/04/2017
CompanyRankvs 470+ SIC 72110 peers83
Show leaderboard
How is this score calculated?
Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.
Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.
Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.
One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.
Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.
Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.
Key FinancialsYear ending 31/12/2025
Net Worth
£84.6M
Balance sheet strength
Cash
£82.4M
Cash in the bank
Net Current Assets
£79.3M
Working capital
Current Assets
£89.0M
Current Liabilities
£9.7M
Fixed Assets
£5.3M
Debtors
£6.6M
Profit After Tax
-£35.3M
Balance Sheet
EstimatesDerived
| Year | Current Ratio | Implied Profit |
|---|---|---|
| 2025 | 9.16 | +£83.6M |
| 2023 | 6.43 | -£3.3M |
| 2020 | 36.29 | +£4.3M |
| 2019 | 16.66 | -£90k |
| 2018 | 30.55 | — |
Derived from filed accounts. Not audited figures.